Moleculin Receives Approval from the UK’s Medicines and Healthcare Products Regulatory Agency for Protocol Amendment to Phase Ia Clinical Trial of WP1122 for the Treatment of COVID-19

Moleculin Biotech, Inc. announced that it has received approval from the United Kingdom’s MHRA to proceed with a first-in-human Phase Ia study to evaluate the safety and pharmacokinetics of WP1122 in healthy volunteers for the treatment of COVID-19.